pharm edaily

[이데일리 석지헌 기자] BioSolution Co. said Wednesday it met with a high-level delegation from China’s Hainan province to discuss policies for bringing its cell-therapy pipeline, including CartiLife, to the Chinese market.

BioSolution CEO Lee Jeong-seon, Chairman Jang Song-sun, Hainan Vice Gove.

The session took place during a Seoul visit by Xie Jing, vice governor of the Hainan provincial people’s government, and Fu Sheng, director general of the Boao Lecheng International Medical Tourism Pilot Zone. The delegation is also meeting the Chinese Embassy, Korean agencies and major companies; BioSolution was the only Korean biotech granted an official meeting.

Seven senior Hainan officials joined the talks, while BioSolution was represented by Chairman Jang Song-sun, Chief Executive Lee Jeong-seon and four other executives.

Both sides reviewed past collaboration and examined Hainan’s “new technology conversion and application” policy, which allows imported cell and gene therapies to be produced and sold locally under the island’s free-trade-port rules.

In February, Hainan enacted regulations enabling Chinese hospitals to seek approval to introduce cell and gene therapies already commercialized overseas if they benefit public health. Hospitals can apply directly to regulators through the “new technology conversion” pathway.

“This high-level meeting confirmed that our long-prepared entry into the Boao Lecheng zone is on track,” Lee said. “We will push ahead with globalizing our entire portfolio from cartilage-repair and osteoarthritis treatments to world-class human-tissue models.”